• Contact
• About APA
• Site Map

• Psychiatric Practice
  • Addiction Psychiatry
  • Ethics
  • Managing Your Practice
  • Medicare Medicaid
  • Practice Guidelines
  • Quality Improvement
• Education & Career Development
  • Educational Initiatives
  • Lifelong Learning & CME
  • Medical Students
  • Meetings
  • Melvin Sabshin Library & Archives
  • Residents
• Research
  • DSM
  • International Programs
  • Psychiatric Research Report
  • Health Policy Analysis
  • APIRE
  • Practice Research Network and Health Services Research
  • Research Training and Funding
  • Research in Residency
  • Research Colloquium for Junior Investigators
  • Endowment Campaign
• Advocacy
  • APA AMA Delegation
  • Communications & Public Affairs
  • Financing Health Care
  • Government Relations
  • Multimedia
  • Political Action Committee
• Newsroom
  • News Releases
  • Annual Reports
  • APA Member and DB/SA Resources
  • APA Daily Bulletin
• Members Corner

• Home
• Research
• DSM
• DSM-V
• Meet the Task Force
• Pine

Daniel Pine, M.D.

Name, Degree:  Daniel S. Pine, M.D.
Role(s) in Task Force and Work Group: Chair, Disorders in Childhood and Adolescence Work Group
Institutional Affiliation(s):  National Institute of Mental Health
City, State:  Bethesda, MD

Biographical Sketch:

Dr. Daniel Pine is currently Chief, with Tenure, Section on Development and Affective Neuroscience, Chief, Emotion and Development Branch, and Chief of Child and Adolescent Research in the Mood and Anxiety Disorders Program of the National Institute of Mental Health Intramural Research Program.  Dr. Pine moved to this position in the fall of 2000, after 10 years of training, teaching, and research at the Department of Child and Adolescent Psychiatry in the New York State Psychiatric Institute and the College of Physicians and Surgeons of Columbia University.  Since graduating from medical school at the University of Chicago, Dr. Pine has been engaged continuously in research focusing on the epidemiology, biology and treatment of psychiatric disorders in children and adolescents.  His areas of expertise include biological and pharmacological aspects of mood, anxiety, and behavioral disorders in children, as well as classification of psychopathology across the lifespan.  This expertise is reflected in a series of more than 190 peer-reviewed papers on these topics.  Dr. Pine also possesses expertise in the biological commonalities and differences among psychiatric disorders of children, adolescents, and adults as well as on interfaces between psychiatric and medical disorders.  Currently, his group at the NIMH is examining the degree to which mood and anxiety disorders in children and adolescents are associated with underlying abnormalities in the amygdala, prefrontal cortex, and other brain regions that modulate activity in these structures.   Dr. Pine also serves as the Chair of the Psychopharmacologic Drug Advisory Committee for the Food and Drug Administration and the Chair of the Developmental Working Group for the DSM-V Task Force.  Dr. Pine has received a number of awards, including Career Development and R01 extramural grant support from the NIMH, a NARSAD Independent Investigator Award, as well as the Blanche Ittelson Award from the American Psychiatric Association for outstanding research contributions to the field of child psychiatry.

Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V :   Three calendar years before  nomination and Each year thereafter through the present calendar year.  (For 2008, activities to date and commitments for remainder of year.)

The two tables below represent Dr. Pine’s disclosure of significant interests and affiliations for:  (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.

Dr. Daniel Pine has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, his aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.

Disclosure of significant interests including:  Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force

Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on  the DSM-V Task Force, to the present.  (For 2008, activities to date and commitments for remainder of year.)